Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jul 10;398(10295):121-130.
doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25.

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M Borobia  1 , Antonio J Carcas  1 , Mayte Pérez-Olmeda  2 , Luis Castaño  3 , María Jesús Bertran  4 , Javier García-Pérez  5 , Magdalena Campins  6 , Antonio Portolés  7 , María González-Pérez  8 , María Teresa García Morales  9 , Eunate Arana-Arri  3 , Marta Aldea  4 , Francisco Díez-Fuertes  5 , Inmaculada Fuentes  10 , Ana Ascaso  7 , David Lora  9 , Natale Imaz-Ayo  3 , Lourdes E Barón-Mira  4 , Antonia Agustí  11 , Carla Pérez-Ingidua  7 , Agustín Gómez de la Cámara  9 , José Ramón Arribas  12 , Jordi Ochando  8 , José Alcamí  5 , Cristóbal Belda-Iniesta  13 , Jesús Frías  14 ; CombiVacS Study Group
Collaborators, Affiliations
Clinical Trial

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M Borobia et al. Lancet. .

Erratum in

  • Department of Error.
    [No authors listed] [No authors listed] Lancet. 2021 Aug 14;398(10300):582. doi: 10.1016/S0140-6736(21)01805-5. Lancet. 2021. PMID: 34391500 Free PMC article. No abstract available.

Abstract

Background: To date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK).

Methods: We did a phase 2, open-label, randomised, controlled trial on adults aged 18-60 years, vaccinated with a single dose of ChAdOx1-S 8-12 weeks before screening, and no history of SARS-CoV-2 infection. Participants were randomly assigned (2:1) to receive either BNT162b2 (0·3 mL) via a single intramuscular injection (intervention group) or continue observation (control group). The primary outcome was 14-day immunogenicity, measured by immunoassays for SARS-CoV-2 trimeric spike protein and receptor binding domain (RBD). Antibody functionality was assessed using a pseudovirus neutralisation assay, and cellular immune response using an interferon-γ immunoassay. The safety outcome was 7-day reactogenicity, measured as solicited local and systemic adverse events. The primary analysis included all participants who received at least one dose of BNT162b2 and who had at least one efficacy evaluation after baseline. The safety analysis included all participants who received BNT162b2. This study is registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739), and is ongoing.

Findings: Between April 24 and 30, 2021, 676 individuals were enrolled and randomly assigned to either the intervention group (n=450) or control group (n=226) at five university hospitals in Spain (mean age 44 years [SD 9]; 382 [57%] women and 294 [43%] men). 663 (98%) participants (n=441 intervention, n=222 control) completed the study up to day 14. In the intervention group, geometric mean titres of RBD antibodies increased from 71·46 BAU/mL (95% CI 59·84-85·33) at baseline to 7756·68 BAU/mL (7371·53-8161·96) at day 14 (p<0·0001). IgG against trimeric spike protein increased from 98·40 BAU/mL (95% CI 85·69-112·99) to 3684·87 BAU/mL (3429·87-3958·83). The interventional:control ratio was 77·69 (95% CI 59·57-101·32) for RBD protein and 36·41 (29·31-45·23) for trimeric spike protein IgG. Reactions were mild (n=1210 [68%]) or moderate (n=530 [30%]), with injection site pain (n=395 [88%]), induration (n=159 [35%]), headache (n=199 [44%]), and myalgia (n=194 [43%]) the most commonly reported adverse events. No serious adverse events were reported.

Interpretation: BNT162b2 given as a second dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile.

Funding: Instituto de Salud Carlos III.

Translations: For the French and Spanish translations of the abstract see Supplementary Materials section.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests CB-I is the deputy general manager of the Instituto de Salud Carlos III. JRA has received fees from Janssen, outside of the submitted work. AMB is principal investigator of clinical trials sponsored by GlaxoSmithKline, Daiichi-Sankyo, Janssen, and Farmalider, outside of the submitted work. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Trial profile 663 individuals were included in the immunogenicity analysis for receptor-binding domain-specific and trimeric spike protein-specific IgG analysis to explore the primary objective of the trial. Secondary objectives to explore functionality of SARS-CoV-2-specific antibodies included 198 individuals randomly selected from both groups and, after a protocol amendment, 151 individuals from Madrid sites for cellular immunity analysis.
Figure 2
Figure 2
Antibody titres Receptor-binding domain (anti-spike protein) antibody titres (A), and trimeric spike protein antibody titres (B), measured in both intervention and control groups on days 0, 7, and 14. *p<0·0001.
Figure 3
Figure 3
Neutralisation responses (A) Neutralising antibodies measured in both intervention and control groups on days 0 and 14. (B) Correlation between NT50 and RBD (anti-spike protein) antibody titres. NT50=titres that achieved 50% neutralisation. RBD=receptor-binding domain. *p<0·0001.
Figure 4
Figure 4
IFN-γ concentrations measured in both intervention and control groups on days 0 and 14 IFN=interferon. *p<0·0001.
Figure 5
Figure 5
Solicited local and systemic adverse reactions in first 7 days after vaccination
See this image and copyright information in PMC

Comment in

References

    1. Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine. 2016;34:413–423. - PubMed
    1. Andreas Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092–2101. - PMC - PubMed
    1. Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397:2043–2046. - PMC - PubMed
    1. Spencer AJ, McKay PF, Belij-Rammerstorfer S, et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat Commun. 2021;12 - PMC - PubMed
    1. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–681. - PMC - PubMed

Publication types

Associated data